Characteristics of patients with recurrent PE
| Patient number . | Age at initial clot (y) . | Sex . | Thrombosis risk factors at recurrence . | Time to recurrence (mo) . | Anticoagulation at time of recurrence . |
|---|---|---|---|---|---|
| 1 | 21 | F | Mitochondrial disease CVC Factor V Leiden heterozygosity | 0.75 | Subtherapeutic enoxaparin |
| 2 | 16 | F | May Thurner syndrome with stent Obesity (BMI = 30 kg/m2) | 2.75 | Enoxaparin |
| 3 | 14 | F | Systemic lupus erythematosus | 3 | Rivaroxaban |
| 4 | 16 | F | Poorly controlled type 1 diabetes mellitus Persistently elevated factor VIII (350% to 400%) | 11 | None |
| 5 | 18 | F | May Thurner syndrome Immobility from anterior cruciate ligament repair before recurrent PE | 24 | None |
| 6 | 17 | M | Respiratory failure from substance overdose | 36 | None |
| 7 | 14 | F | Chronic pancreatitis CVC for total parenteral nutrition | 42 | None |
| 8 | 18 | F | APS Obesity (BMI = 55 kg/m2) | 51 | Rivaroxaban |
| Patient number . | Age at initial clot (y) . | Sex . | Thrombosis risk factors at recurrence . | Time to recurrence (mo) . | Anticoagulation at time of recurrence . |
|---|---|---|---|---|---|
| 1 | 21 | F | Mitochondrial disease CVC Factor V Leiden heterozygosity | 0.75 | Subtherapeutic enoxaparin |
| 2 | 16 | F | May Thurner syndrome with stent Obesity (BMI = 30 kg/m2) | 2.75 | Enoxaparin |
| 3 | 14 | F | Systemic lupus erythematosus | 3 | Rivaroxaban |
| 4 | 16 | F | Poorly controlled type 1 diabetes mellitus Persistently elevated factor VIII (350% to 400%) | 11 | None |
| 5 | 18 | F | May Thurner syndrome Immobility from anterior cruciate ligament repair before recurrent PE | 24 | None |
| 6 | 17 | M | Respiratory failure from substance overdose | 36 | None |
| 7 | 14 | F | Chronic pancreatitis CVC for total parenteral nutrition | 42 | None |
| 8 | 18 | F | APS Obesity (BMI = 55 kg/m2) | 51 | Rivaroxaban |
CVC, central venous cathether; F, female; M, male.